These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors. Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A Digestion; 2017; 96(1):52-59. PubMed ID: 28662503 [TBL] [Abstract][Full Text] [Related]
9. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868 [TBL] [Abstract][Full Text] [Related]
10. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study. Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K Digestion; 2018; 97(1):70-75. PubMed ID: 29393198 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux. Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M Digestion; 2020; 101(2):174-183. PubMed ID: 30897577 [TBL] [Abstract][Full Text] [Related]
13. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606 [TBL] [Abstract][Full Text] [Related]
14. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis. Iwakiri K J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181 [TBL] [Abstract][Full Text] [Related]
15. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials. Simadibrata DM; Lesmana E; Fass R J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152 [TBL] [Abstract][Full Text] [Related]
16. Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis. Takenouchi N; Hoshino S; Hoshikawa Y; Tanabe T; Koeda M; Momma E; Ishikawa Y; Kawami N; Kaise M; Iwakiri K Esophagus; 2020 Jan; 17(1):87-91. PubMed ID: 31679094 [TBL] [Abstract][Full Text] [Related]